Search Results
May 31, 2026, 20:00 ET 德昇濟醫藥在ASCO 2026公布Elisrasib（D3S-001）一線治療數據；新一代KRAS G12C抑制劑在初治NSCLC中展現裡程碑式療效
israsib新的或非預期安全性信號，整體安全性優於帕博利珠單抗聯合化療這一當前標准治療方案。專家點評上海交通大學醫學院附屬胸科醫院教授、本次研究報告人陸舜教授表示：「elisrasib一線治療數據令人鼓舞，無論作為單藥還是與帕博利珠單抗聯合應用，在不同 PD-L1 表達亞組中均展現出穩定強效的抗腫瘤活性。其耐受性良好且起效迅速，充分彰顯了這款藥物用於 KRAS G12C 突變非小細胞肺癌（NSCLC）患者的臨床應用潛力。」德昇濟醫藥創始人、董事長兼首席執行官陳之鍵博士表示：「elisrasib在一線NSCLC中的單藥及聯合治療均展現出極
More news about: 德昇濟醫藥（D3 Bio）
May 31, 2026, 20:00 ET ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO
(Ta/T1) disease. This represents a synergy of direct oncolysis and immune activation, further enhanced by the integrated effects of exogenous IL-12 and PD-1 antibody expressions within tumor cells. We are committed to rapidly advancing our clinical program to reach broader bladder cancer patient populations
More news about: ImmVira Group
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
subgroupsOS benefit with ivonescimab was observed consistently regardless of PD-L1 expression status: HR=0.68 in the PD-L1 TPS ≥1% subgroup and HR=0.64 in the TPS <1% subgroup; HR=0.67 in the PD-L1 TPS 1–49% subgroup and HR=0.64 in the TPS ≥50% subgroup.The OS benefit was also
More news about: Akeso, Inc.
May 31, 2026, 08:29 ET RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
regimens.Cohort 1 evaluated RYBREVANT FASPRO™ as monotherapy in patients with R/M HNSCC who had received prior platinum-based chemotherapy and PD-1/PD-L1 immunotherapy. Patients with HPV-positive oropharyngeal squamous cell carcinoma were excluded, as well as those with prior anti-EGFR therapy.RYBREVANT
More news about: Johnson & Johnson
May 30, 2026, 20:09 ET Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026
oral presentation. The other study reported results for golidocitinib, a JAK1-selective inhibitor, combined with an anti-PD-1 antibody as a first-line treatment for PD-L1-positive, advanced NSCLC without driver mutations.
More news about: Dizal Pharmaceutical
May 30, 2026, 20:00 ET 榮登《柳葉刀》主刊！蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療 PD-L1 陽性 NSCLC III期重磅結果發表
/美通社/ -- 2026年5月31日，四川科倫博泰生物醫藥股份有限公司(下稱「科倫博泰」或「公司」6990.HK)宣布，公司自主研發的靶向人滋養細胞表面抗原2(TROP2)的抗體偶聯藥物(ADC)蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊®)聯合帕博利珠單抗(可瑞達®[1]，默沙東的抗程序性細胞死亡蛋白-1(PD-1)單抗)一線治療程序性細胞死亡配體1(PD-L1)腫瘤細胞陽性比例分數(TPS)≥1%非小細胞肺癌(NSCLC)的III期臨床研究(OptiTROP-Lung05)結果榮登國際頂級醫學期刊《柳葉刀》（The
More news about: 科倫博泰
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
combination with pembrolizumab (KEYTRUDA®[1], MSD's anti-programmed cell death protein 1 (PD-1) antibody) as first-line treatment for Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), have been published in the prestigious international
More news about: Kelun-Biotech
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
exceeds other established and emerging ADC targets.SCLC – SEZ6 expression was at least 3-fold higher than HER2, B7-H3, DLL3, PD-L1 and PD-1.Prostate neuroendocrine carcinoma – SEZ6 expression was 2- to 6-fold higher than B7-H3, DLL3 and TROP2.Among SCLC molecular
More news about: Whitehawk Therapeutics, Inc.
May 30, 2026, 00:30 ET 2026 ASCO | 蘆康沙妥珠單抗(sac-TMT) III期OptiTROP-Lung05研究成果於ASCO口頭報告和《柳葉刀》同步發佈
2026年5月30日，四川科倫博泰生物醫藥股份有限公司(下稱「科倫博泰」或「公司」 6990.HK)宣佈，在美國芝加哥舉行的2026年美國臨床腫瘤學會(ASCO)年會上，同濟大學附屬東方醫院周彩存教授以口頭報告形式公佈了TROP2 ADC蘆康沙妥珠單抗(sac-TMT，亦稱SKB264/MK-2870)(佳泰萊®)聯合帕博利珠單抗(可瑞達®[1]，默沙東的抗程序性細胞死亡蛋白-1(PD-1)單抗)一線治療程序性細胞死亡配體1(PD-L1)腫瘤細胞陽性比例分數(TPS)≥1%非小細胞肺癌(NSCLC)的III期OptiTROP-Lung05研究結果(摘要編號#8506，肺癌-轉移性非小細胞)。
More news about: 科倫博泰
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
combination with pembrolizumab (KEYTRUDA®[1], MSD's anti-programmed cell death protein 1 (PD-1) antibody) as first-line treatment for Programmed Death-Ligand 1 (PD-L1) Tumor Proportion Score (TPS)≥1% non-small cell lung cancer (NSCLC), was presented as an oral presentation by Professor
More news about: Kelun-Biotech
May 29, 2026, 09:30 ET Acer Unveils Sub-1kg TravelMate P6 14 AI Business Laptop with New Acer Comfort Touch Design for Premium Luxury on the Move
magnesium-aluminum alloy. The device is equipped with a 71 Wh battery that supports fast charging[5] via high-speed Power Delivery (PD) recovery and offers up to 30 hours of battery life[1], ensuring professionals can work through the longest days without a recharge. High-speed
More news about: Acer
May 29, 2026, 08:00 ET SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund
platforms. Earlier this year, the company relocated its headquarters and research center to Songdo, Incheon, integrating R&D, process development (PD), business development (BD), and marketing functions to further enhance its global competitiveness.Jaeyong Ahn, CEO of SK bioscience said, "Being
More news about: SK bioscience
May 28, 2026, 19:26 ET Phanes Therapeutics Announces Updated Phase 2 Clinical Trial Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline Treatment of Metastatic PDAC at the 2026 ASCO Annual Meeting
immunity enhancer (I2E), an emerging class of immuno-oncology (IO) agents. Unlike immune checkpoint inhibitors (ICIs) (also known as anti-PD1/anti-PD-L1 drugs) which activate T cells to kill cancer cells, I2Es activate macrophages and dendritic cells to recognize and destroy cancer cells,
More news about: Phanes Therapeutics, Inc.
May 28, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
combination with cemiplimab (PD-1 inhibitor) as a first-line treatment for patients with unresectable locally advanced or metastatic melanoma" "did not each statistical significance for the primary endpoint of improvement in progression-free survival (PFS) compared to pembrolizumab (PD-1 inhibitor) monotherapy." On
More news about: Pomerantz LLP
May 28, 2026, 09:01 ET Acer Broadens Portfolio with Two New Laptops Powered by the Latest Snapdragon Processors
results)Up to 16.5 hours under a web browsing scenario100 W PD adapter for fast chargingNetworking
More news about: Acer
May 28, 2026, 09:00 ET ImmunoGenesis Appoints Chief Medical Officer
immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic immune checkpoint inhibitor targeting PD-L1 and PD-L2. IMGS-001 is currently in a phase 1a/b clinical trial for the treatment of immune-excluded tumors, which account for more than half of all cancers.
More news about: Immunogenesis Inc.
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
MD, FCS director of drug development, SCRI at Lake Nona Drug Development UnitPhase 1 dose escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition.The following FCS principal investigators
More news about: Florida Cancer Specialists & Research Institute
May 28, 2026, 08:00 ET Blood Cancer United Data at 2026 ASCO and EHA Highlight Beat AML Progress, Patient Experience Insights and Access Barriers
VISPA-CEL, an Allogeneic Anti-CD19 CAR-T Cell Therapy with a PD-1 Knockout, in Patients with Relapsed/Refractory B-Cell Non-HodgkinLymphoma (ANTLER Phase 1 Clinical Trial)
More news about: Blood Cancer United® formerly The Leukemia & Lymphoma Society
May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
potential overall survival (OS) benefit that simultaneously targets PD-L1 and the co-stimulatory receptor 4-1BB. Developed using Leads Biolabs' proprietary X-Body bispecific platform, Opamtistomig is designed to simultaneously block PD-1/L1 immune suppression and conditionally activate 4-1BB, an agonist
More news about: Nanjing Leads Biolabs Co., Ltd.
May 27, 2026, 20:00 ET Antengene Receives CDE Endorsement to Initiate Pivotal Phase III CLINCH-3 Study of ATG-022 in CLDN18.2+ Advanced Gastric/GEJ Cancer
commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using
More news about: Antengene Corporation Limited
May 27, 2026, 17:00 ET Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
Importantly, survival benefit with the addition of tislelizumab was suggested across PD-L1-defined subgroups, including in patients with PD-L1-negative tumors, a population that has historically derived limited benefit from PD-1-based approaches.""We believe the HERIZON-GEA-01 results, together with
More news about: Jazz Pharmaceuticals plc
May 27, 2026, 09:31 ET Sensorium Therapeutics to Present SNTX-2643 Mechanistic Data and Phase 1a Study Design at ASCP 2026
placebo-controlled, and open-label (food-effect cohort) clinical study designed to characterize the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profile of SNTX-2643 in healthy adult volunteers following single-dose administration, and to inform the design of subsequent clinical studies.The
More news about: Sensorium Therapeutics
May 27, 2026, 09:00 ET IMMP Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Immutep Limited Securities Lawsuit - Contact Levi & Korsinsky
by full enrollment completion by Q3 2026Prior TACTI-002 and INSIGHT-003 trials were cited as demonstrating efti enhances anti-PD-1 therapy "regardless of PD-L1 expression levels"As late as February 6, 2026, the CEO described enrollment as proceeding at an "excellent pace" that "speaks
More news about: Levi & Korsinsky, LLP
May 27, 2026, 08:08 ET SynuSight-Shanghai Jiao Tong University Collaboration Published in Cell, Advancing Diagnostic Classification of Synucleinopathies
for diagnostic tools based on disease-specific pathological biomarkers.Although both PD and MSA are associated with abnormal aggregation of α-synuclein, they differ significantly in cellular pathology. PD is primarily characterized by α-syn aggregation within neurons, leading to the formation of
More news about: SynuSight Biotech
May 27, 2026, 08:00 ET Biohub releases a world model of protein biology
model to design protein binders against five targets at the center of cancer and immunology research — EGFR and PDGFRβ (implicated in tumor growth), PD-L1 and CTLA-4 (immune checkpoints that cancer cells exploit to evade detection), and CD45 (a regulator of immune cell signaling). Designs achieved hit
More news about: Biohub